Breaking News, Collaborations & Alliances

CDMO BioCina Partners with CelluTx

Acquires exclusive CDMO rights for minicircle DNA technology platform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the exclusive rights to utilize CelluTx’s recombination-based plasmid system (RBPS) technology with BioCina’s CDMO clients. RBPS is a cutting-edge technology for minicircle DNA (mcDNA) production involving site-specific recombination within a bacterial host, to separate the minicircle containing the gene of interest from the rest of the plasmid backbone, including the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters